MedTrace Logo

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

NCT06823947 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-03-09

No results posted yet for this study

Summary

Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension. Part 3 : To assess the safety profile of repeated dosing of KK3910 in an additional hypertension cohort.

Conditions

  • Healthy Volunteers Essential Hypertension

Interventions

DRUG

Placebo

Placebo is administered single dose or multiple dose by SC injection.

DRUG

KK3910

KK3910 is administered single dose or multiple dose by SC injection.

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tatsuhiko Makine · Kyowa Kirin Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-03
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06823947 on ClinicalTrials.gov